eHighlights

REGROUP trial: Major adverse cardiac events results similar for endoscopic vein harvesting compared to open vein harvesting for CABG

There were no significant differences in major adverse cardiac events for endoscopic vein harvesting compared to open vein harvesting for CABG, according to Randomized Endovein Graft Prospective (REGROUP) results presented at Scientific Sessions 2018 in Chicago.

PIONEER-HF: Sacubitril/valsartan reduced cardiovascular biomarker in patients with reduced ejection fraction hospitalized for acute decompensated heart failure

Compared to enalapril, sacubitril/valsartan was associated with a greater reduction in the biomarker N-terminal pro-brain natriuretic peptide and re-hospitalization for heart failure, according to a study presented at Scientific Sessions 2018 in Chicago.

BRIDGE trial suggests quality improvement interventions may increase use of evidence-based therapies

The BRIDGE Cardiovascular Prevention Cluster Randomized Trial found that a multifaceted quality improvement educational intervention significantly increased the use of evidence-based therapies for cardiovascular disease in a low- and middle-income setting.

Results from DECLARE trials show drug may reduce CV death or hospitalizations for HF patients with Type 2 diabetes

The SGLT-2 inhibitor dapagliflozin met one primary composite endpoint with a statistically significant reduction in heart failure hospitalization or cardiovascular death versus placebo, according to results presented in a Late-Breaking Clinical Trial session at Scientific Sessions 2018 in Chicago.

Yoga may have potential for cardiac rehab in low- and middle-income settings

Yoga-based cardiac rehabilitation may have potential in post-myocardial infarction patients compared with enhanced standard care, according to a multicenter randomized controlled trial in India.

REDUCE-IT finds medication added to statins reduces risks among patients with high triglycerides

Primary results from the REDUCE-IT study found that supplemental icosapent ethyl, a prescription medication approved to reduce triglycerides ≥ 500 mg/dL, significantly reduced the risk of important cardiovascular events by 25 percent.

VITAL trial considers omega-3 fatty acids, vitamin D in CV protection and cancer mortality

VITAL trial considers omega-3 fatty acids, vitamin D in CV protection and cancer mortality
Marine omega-3 fatty acids may provide a cardioprotective role, while vitamin D3 supplementation appears to benefit cancer mortality, according to principal results from the National Institutes of Health-funded VITamin D and OmegA-3 TriaL.

Top